Sinopharm Group Co. Ltd.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sinopharm Group Co. Ltd.'s yearly results (2022–2025), compared with companies in China. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 7.2 times. Higher than 87% of companies in China.
- Cash Locked Ratio: For every ¥100 of sales, ¥16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥11 tied up three years earlier. More money tied up than 87% of companies in China.
- Debt Due Cover Ratio: Debt due within a year is covered 0.2 times by its yearly operating cash. Lower than 85% of companies in China.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
7.2×Over the last 3 years its own operating cash covered its investment spending (capex) 7.2 times.
Higher than 87% of companies in China.
Cash Locked Ratio
¥16For every ¥100 of sales, ¥16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥11 tied up three years earlier.
More money tied up than 87% of companies in China.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 77% of companies in China.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +4% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+4% / +7%In 3 years sales changed by +4% while total assets changed by +7%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
0.2×Debt due within a year is covered 0.2 times by its yearly operating cash.
Lower than 85% of companies in China.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
97%Of every ¥100 the company owns, ¥97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 54% of companies in China.
Tangible Net Worth Ratio
88%Of every ¥100 of net worth, ¥88 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 65% of companies in China.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Sinopharm Group Co. Ltd. owes ¥0.66 for every ¥1 it owns. Net profit rose 1% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Compared with companies in China · latest annual results Dec 2025.
P/E ratio
6.2Investors pay ¥6.2 for every ¥1 of Sinopharm Group Co. Ltd.'s yearly profit, lower than 93% of companies in China.
P/B ratio
0.49The share price is 0.49 times Sinopharm Group Co. Ltd.'s book value per share, lower than 94% of companies in China.
Market cap
HK$48.1 BThe total market value of all of Sinopharm Group Co. Ltd.'s shares at today's price (share price × number of shares), smaller than 87% of companies in China. PosiCap size class: Meso Cap.
Net worth (book value)
¥84.0 BWhat Sinopharm Group Co. Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Dec 2025).
Return on equity (ROE)
8.0%Sinopharm Group Co. Ltd. earned 8.0% on its shareholders' money over the last year, lower than 71% of companies in China.
Owes vs Owns
0.66×Sinopharm Group Co. Ltd. owes ¥0.66 for every ¥1 it owns (moderate), higher than 83% of companies in China.
Dividend yield
5.04%Sinopharm Group Co. Ltd. pays 5.04% of its share price as dividends a year, higher than 66% of dividend-paying companies in China.
Revenue growth
-2%Revenue fell 2% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Profit growth
+1%Net profit rose 1% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Profit margin
1.2%Sinopharm Group Co. Ltd. keeps ¥1 of every ¥100 of revenue as net profit.
Cash quality
2.0×Cash from Sinopharm Group Co. Ltd.'s business was 2.0× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
7.4×Sinopharm Group Co. Ltd.'s operating profit covered its interest costs 7.4 times in the year to Dec 2025.
Cash vs debt
Net debtSinopharm Group Co. Ltd. had ¥22.2 B more debt than cash (net debt) at Dec 2025.
Questions
What is Sinopharm Group Co. Ltd.'s P/E ratio?
Investors pay ¥6.2 for every ¥1 of Sinopharm Group Co. Ltd.'s yearly profit, lower than 93% of companies in China.
What is Sinopharm Group Co. Ltd.'s return on equity?
Sinopharm Group Co. Ltd. earned 8.0% on its shareholders' money over the last year, lower than 71% of companies in China.
How much does Sinopharm Group Co. Ltd. owe compared with what it owns?
Sinopharm Group Co. Ltd. owes ¥0.66 for every ¥1 it owns (moderate), higher than 83% of companies in China.
Does Sinopharm Group Co. Ltd. pay a dividend?
Yes. Sinopharm Group Co. Ltd. pays 5.04% of its share price as dividends a year, higher than 66% of dividend-paying companies in China.
Is Sinopharm Group Co. Ltd.'s revenue growing?
Revenue fell 2% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.